TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›CDLX›Financials
Annual statements · SEC XBRL · FY2016 – FY2025

Cardlytics, Inc. (CDLX) financials

Income statement

Cardlytics, Inc. (CDLX) income statement, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$113M$130M$151M$210M$187M$259M$277M$285M$256M$212M
Revenue growth—15.6%15.6%39.6%-11.2%38.5%7.1%3.0%-10.4%-16.9%
Operating income-$56.2M-$17.1M-$40.9M-$17.3M-$53.9M-$123M-$458M-$136M-$195M-$102M
Operating margin-49.8%-13.1%-27.2%-8.2%-28.9%-47.4%-165.2%-47.5%-76.5%-48.0%
Net income-$75.7M-$19.6M-$53.0M-$17.1M-$55.4M-$129M-$465M-$135M-$189M-$103M
Net margin-67.1%-15.1%-35.2%-8.1%-29.7%-49.7%-167.9%-47.2%-74.1%-48.7%
EPS (diluted)-$32.48-$7.86-$2.79-$0.72-$2.04-$3.99-$13.92-$3.69-$3.91-$1.95

Cash flow

Cardlytics, Inc. (CDLX) cash flow, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$32.5M-$22.1M-$19.0M$11.5M-$7.60M-$38.5M-$53.9M-$185K-$8.82M$9.29M
Capital expenditures$1.83M$1.22M$5.92M$8.28M$5.41M$3.11M$1.17M$667K$1.56M$480K
Free cash flow-$34.3M-$23.3M-$24.9M$3.18M-$13.0M-$41.6M-$55.1M-$852K-$10.4M$8.81M
Share buybacks————$0.00$0.00$40.0M$0.00$0.00—

Balance sheet

Cardlytics, Inc. (CDLX) balance sheet, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$22.8M$21.3M$39.6M$104M$293M$233M$122M$91.8M$65.6M$48.7M
Total assets—$101M$154M$224M$423M$1.26B$691M$574M$393M$286M
Total liabilities———$81.0M$265M$573M$480M$439M$323M$292M
Long-term debt—$57.0M$46.7M$13.0K$174M$184M$226M—$219M$213M
Shareholders' equity-$217M-$209M$52.0M$143M$157M$691M$212M$135M$70.0M-$6.51M
Retained earnings—-$268M-$321M-$339M-$394M-$523M-$977M-$1.11B-$1.30B-$1.40B
Shares (wtd avg diluted)—3.44M22.5M—27.2M32.2M33.4M36.5M48.4M53.1M

Every figure is extracted from Cardlytics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Cardlytics, Inc.'s annual revenue?
Cardlytics, Inc. (CDLX) reported $212M of revenue for fiscal year 2025 — down 16.9% from $256M in FY2024, per its annual report filed with the SEC.
Is Cardlytics, Inc. profitable?
Not in FY2025 — CDLX reported a net loss of $103M, per SEC filings.
What is Cardlytics, Inc.'s free cash flow?
$8.81M in FY2025 (operating cash flow $9.29M minus $480K of capital expenditures), from the SEC cash-flow statement.
Does CDLX pay a dividend?
Cardlytics, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full CDLX analysis — verdict, score & filings →Is CDLX a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.